FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

The FDA approved a supplemental application for Multaq (dronedarone) submitted by Sanofi-Aventis U.S. LLC, resulting in labeling updates for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter

Drugs mentioned

• Multaq (dronedarone)

Snippet

SUPPL AP for MULTAQ (DRONEDARONE)